Screener
Allogene Therapeutics ALLO Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Allogene Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
FAQ
- What is Allogene Therapeutics's free cash flow margin?
- Allogene Therapeutics (ALLO) reported free cash flow margin of -913,609.1% in Q4 2024.
- How has Allogene Therapeutics's free cash flow margin changed year-over-year?
- Allogene Therapeutics's free cash flow margin decreased by 262.8% year-over-year, from -251,841.1% to -913,609.1%.
- What is the long-term trend for Allogene Therapeutics's free cash flow margin?
- Over 3 years (2021 to 2024), Allogene Therapeutics's free cash flow margin has grown at a 1616.1% compound annual growth rate (CAGR), from -180.8% to -913,609.1%.
- What does free cash flow margin mean?
- Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.
Ask your AI about Allogene Therapeutics's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude